Semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Key points:

• Synthetic peptide analog of human GLP-1
• 94% sequence homology to native GLP-1
• Molecular formula: C165H261N43O52
• Molecular weight: 4113.6 g/mol
• Developed by Novo Nordisk
• Approved for type 2 diabetes (2017) and weight management (2021)
• Available in injectable (Ozempic, Wegovy) and oral (Rybelsus) formulations

Semaglutide works through several mechanisms:

• 1 Activates GLP-1 receptors in pancreatic beta cells, stimulating insulin release
• 2 Suppresses glucagon secretion from pancreatic alpha cells
• 3 Slows gastric emptying, reducing postprandial glucose spikes
• 4 Increases satiety and reduces appetite through central nervous system effects
• 5 Enhances beta-cell function and insulin sensitivity
• 6 Promotes weight loss through reduced caloric intake and increased energy expenditure
• 7 Improves cardiovascular risk factors

• Significantly reduces HbA1c levels (1.5-2% reduction in clinical trials)
• Improves fasting and postprandial glucose control
• Reduces risk of major adverse cardiovascular events

• Produces substantial weight loss (15-20% of body weight in clinical trials)
• Improves obesity-related comorbidities
• Maintains weight loss long-term with continued use

• Reduces risk of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke
• Improves blood pressure and lipid profiles
• Potential benefits in heart failure patients

• Reduces liver fat content
• Improves markers of liver function
• Potential to prevent progression to non-alcoholic steatohepatitis (NASH)

• Emerging evidence for potential benefits in Alzheimer's and Parkinson's disease
• May improve cognitive function in patients with type 2 diabetes

• Starting dose: 0.25 mg once weekly for 4 weeks
• Maintenance dose: 0.5 mg once weekly
• Can be increased to 1 mg or 2 mg once weekly if needed

• Starting dose: 3 mg once daily for 30 days
• Maintenance dose: 7 mg once daily
• Can be increased to 14 mg once daily if needed

• Starting dose: 0.25 mg once weekly for 4 weeks
• Dose escalation: Increase dose every 4 weeks (0.5 mg, 1 mg, 1.7 mg)
• Maintenance dose: 2.4 mg once weekly

Semaglutide injectable formulations come as pre-filled, disposable pens:

• 1 Remove pen from refrigerator 30 minutes before injection
• 2 Check that the solution is clear and colorless
• 3 Attach a new needle to the pen
• 4 Prime the pen before first use
• 5 Dial the correct dose
• 6 Choose injection site and clean with alcohol swab
• 7 Insert needle and inject full dose
• 8 Hold needle in place for 6 seconds after injection
• 9 Remove and dispose of needle safely

• Inject into abdomen, thigh, or upper arm
• Rotate injection sites
• Administer once weekly, same day each week

• Take on an empty stomach when you first wake up
• Swallow tablet whole with a sip of plain water (no more than 4 ounces)
• Wait at least 30 minutes before eating, drinking, or taking other oral medications

• Common combination for type 2 diabetes
• May enhance glucose-lowering effects

• Potential for additive effects on glucose control and weight loss
• Monitor for dehydration and ketoacidosis

• Can be used together, but may increase risk of hypoglycemia
• Insulin dose may need to be reduced

Semaglutide is a prescription medication and should only be obtained through licensed pharmacies with a valid prescription from a healthcare provider.

Generally considered safe when used as directed, but potential side effects include:

• Nausea, vomiting, diarrhea (most common)
• Abdominal pain
• Constipation
• Headache
• Fatigue
• Increased risk of pancreatitis (rare)
• Potential risk of medullary thyroid carcinoma (animal studies only)

Long-term safety data beyond 2 years is limited.

• FDA-approved for type 2 diabetes and weight management
• Prescription-only medication
• Legal status may vary in other countries

• Store unopened pens in refrigerator (36°F to 46°F or 2°C to 8°C)
• After first use, can be stored at room temperature (59°F to 86°F or 15°C to 30°C) for up to 56 days
• Do not freeze
• Protect from light
• Keep out of reach of children

Most patients see significant improvements in blood glucose within 4-8 weeks. Weight loss typically becomes noticeable within 4-12 weeks.

No, semaglutide is not approved for use in type 1 diabetes.

Semaglutide is not recommended during pregnancy due to potential risks to the fetus.

Semaglutide has shown superior efficacy in glucose control and weight loss compared to most other GLP-1 receptor agonists in clinical trials.

Semaglutide represents a significant advancement in the treatment of type 2 diabetes and obesity. Its unique mechanism of action, combining glucose control with substantial weight loss and cardiovascular benefits, makes it a valuable option for many patients. The availability of both injectable and oral formulations offers flexibility in treatment approaches.However, its use should be carefully considered in the context of individual patient factors, potential side effects, and cost. As with any medication, semaglutide should be used under the guidance of a healthcare professional, with regular monitoring for efficacy and safety.

• 1 Marso SP, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834-1844.
• 2 Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002.
• 3 Pratley R, et al. (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology, 6(4), 275-286.
• 4 Newsome PN, et al. (2021). A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine, 384(12), 1113-1124.
• 5 Aroda VR, et al. (2019). PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care, 42(9), 1724-1732.